Clinical trials
Pharming announces enrolment of first patient in multicenter Phase IIb clinical trial of RUCONEST® for the prevention of acute kidney injury after myocardial infarction
Pharming Group N.V. announces that the first patient has been enrolled in a Phase IIb double-blind, randomized, controlled study to assess the efficacy of RUCONEST® (recombinant human C1 esterase inhibitor, or “rhC1INH”) for the prevention of acute kidney injury after non-ST elevation myocardial infarction at the University Hospital Basel, Switzerland.
''If found to be efficacious, RUCONEST® could make a significant contribution to improving the life expectancy and quality of life of patients suffering from kidney damage.”
- Bruno Giannetti – CMO